Dr. Stupp on Final Results for TTFields Added to Chemo in Glioblastoma

Roger Stupp, MD
Published: Sunday, Apr 02, 2017


Roger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.
 
This study aimed to improve survival in glioblastoma, which is the most aggressive and malignant primary brain tumor in adults. The study involved 80 centers worldwide and randomized a total of 695 patients to receiving either standard of care – either temozolomide/radiation, followed by temzolomide, or temozolomide/radiation, followed by temozolomide plus TTFields.
 
The results demonstrated a 37% reduction in risk of death when adding TTFields to temozolomide/chemotherapy. To illustrate those results at 2 years, this means the overall survival is increasing from 30% to 43%, and there is a maintenance of this absolute benefit at 3, 4, and even 5 years, Stupp explains.

<<< View more from the 2017 AACR Annual Meeting

Roger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.
 
This study aimed to improve survival in glioblastoma, which is the most aggressive and malignant primary brain tumor in adults. The study involved 80 centers worldwide and randomized a total of 695 patients to receiving either standard of care – either temozolomide/radiation, followed by temzolomide, or temozolomide/radiation, followed by temozolomide plus TTFields.
 
The results demonstrated a 37% reduction in risk of death when adding TTFields to temozolomide/chemotherapy. To illustrate those results at 2 years, this means the overall survival is increasing from 30% to 43%, and there is a maintenance of this absolute benefit at 3, 4, and even 5 years, Stupp explains.

<<< View more from the 2017 AACR Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x